Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorUniversity of Chicago
About this trial
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
Eligibility criteria
Qualifiers
Age 18-75 years
BMI greater than or equal to 30 kg/m2
Paroxysmal AF or persistent AF, in whom catheter ablation (CA) for AF is expected within 1 year (A group) or in whom catheter ablation is NOT expected within 1 year (M group)
Ability to provide informed consent before any trial-related activities.
Disqualifiers
Current use of GLP-1 RA (glucagon-like peptide receptor agonists) or DPP4 (Dipeptidyl peptidase-4)-inhibitors or use within the last 90 days prior to screening
Current antiobesity medication use or use within the last 90 days prior to screening
A self-reported change in body weight of > 5 kg (11 lb.) within 30 days before screening
History of bariatric surgery
Trial design
Treatments tested in this trial
- Semaglutide
- Placebo
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov